Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) posted its quarterly earnings results on Monday. The specialty pharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by $0.07, Bloomberg Earnings reports. The business had revenue of $0.09 million during the quarter. Acura Pharmaceuticals had a return on equity of 112.19% and a net margin of 14.91%.

Acura Pharmaceuticals (NASDAQ:ACUR) opened at 0.4695 on Tuesday. The firm’s market cap is $5.58 million. The firm has a 50-day moving average of $0.51 and a 200 day moving average of $0.57. Acura Pharmaceuticals has a 52-week low of $0.40 and a 52-week high of $1.87.

ILLEGAL ACTIVITY NOTICE: “Acura Pharmaceuticals, Inc. (ACUR) Issues Quarterly Earnings Results” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of international copyright & trademark laws. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/08/15/acura-pharmaceuticals-inc-acur-issues-quarterly-earnings-results.html.

Acura Pharmaceuticals Company Profile

Acura Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products.

Earnings History for Acura Pharmaceuticals (NASDAQ:ACUR)

Receive News & Ratings for Acura Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acura Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.